Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant

Pastore, Gabiria; Polvere, Jacopo; Fiorino, Fabio; Lucchesi, Simone; Montesi, Giorgio; Rancan, Ilaria; Zirpoli, Sara; Lippi, Arianna; Durante, Miriam; Fabbiani, Massimiliano; Tumbarello, Mario; Montagnani, Francesca; Medaglini, Donata; Ciabattini, Annalisa

doi:10.1080/14760584.2024.2333952

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant

Cited by 2 publications

References 69 publications

Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial

Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial

Longitudinal Immunogenicity Study of SARS-CoV-2 mRNA Vaccines Across Subjects with Different Immunocompromising Conditions: Heterogeneity in the Immune Response and Crucial Role of the Booster Dose

Contact Info

Product

Resources

About